Parkinson disease

Selective D1/D5 Receptor Agonism in Parkinson Disease: Insights from the TEMPO-3 Phase 3 Trial of Tavapadon

By MedXY 03/27/2026

The Phase 3 TEMPO-3 trial demonstrates that tavapadon, a novel selective D1/D5 agonist, significantly improves daily 'good-on-time' and reduces 'off-time' in Parkinson’s disease patients with motor fluctuations, presenting a potential shift in adjunctive therapy.

Neurology news Respiratory

Early CPAP Intervention May Mitigate Parkinson Disease Risk in Patients with Obstructive Sleep Apnea

By MedXY 01/02/2026

A massive cohort study of 11.3 million US veterans reveals that obstructive sleep apnea is an independent risk factor for Parkinson disease, but early treatment with CPAP significantly reduces this risk, particularly in women.

Neurology news

Sustained Symptom Control over Five Years: Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson Disease

By MedXY 09/26/2025

Five-year follow-up from the INTREPID trial confirms that subthalamic nucleus deep brain stimulation significantly improves motor symptoms, reduces dyskinesia, lowers medication needs, and enhances daily living activities in moderate to advanced Parkinson disease patients, with an acceptable safety profile.

Clinical Updates Neurology news Specialties Urology

Behavioral Therapy Matches Drug Efficacy for Overactive Bladder in Parkinson’s Disease: Insights from a Randomized Noninferiority Trial

By MedXY 09/11/2025

A 12-week randomized trial demonstrates that behavioral therapy is noninferior to solifenacin in treating overactive bladder symptoms in Parkinson disease, with fewer adverse effects, supporting behavioral therapy as a frontline treatment option.

Clinical Updates Family Medicine & Nutrition Neurology news Radiology Specialties

Physical Exercise Slows Neurodegeneration and Cognitive Decline in Early Parkinson Disease: Insights from Longitudinal MRI Analysis

By MedXY 08/24/2025

Regular physical activity in early Parkinson disease patients is linked to slower brain atrophy in temporoparietal and limbic regions, mediating better preservation of memory and attention over four years.

Neurology news Specialties

Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease

By MedXY 08/17/2025

This study explores medication use and its impact on 8-year mortality among patients with Parkinson disease, identifying potential drug repurposing candidates for treatment.